ArticleGut microbes
Host-mycobiome metabolic interactions in health and disease.
Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- Mass spectrometry-based metabolomics approaches to interrogate host-microbiome interactions in mammalian systems.Natural product reports · 2026Review
- Machine learning-based assessment of the healthy human gut mycobiota landscape using ITS1 DNA metabarcoding data.BioData mining · 2026Article
- Host-pathogen interactions in periodontitis: an integrative interkingdom perspective.Frontiers in immunology · 2026Review
- The role of gut mycobiome in responses to cancer immunotherapy.Gut microbes · 2025Review
- Microbial Modulation of the Gut-Liver Axis in Autoimmune Liver Diseases.Seminars in liver disease · 2025Review
- Innovative engineering approaches to model host-microbiome interactions in vitro.Advanced drug delivery reviews · 2025Review
- Microbiome Signatures and Inflammatory Biomarkers in Culture-Negative Neonatal Sepsis.Applied microbiology (Basel, Switzerland) · 2025Article
- The Interplay between the Gut and Ketogenic Diets in Health and Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Landscape-scale endophytic community analyses in replicated grapevine stands reveal that dieback disease is unlikely to be caused by specific fungal communities.Applied and environmental microbiology · 2025Article
- Stepping out of the dark: how metabolomics shed light on fungal biology.FEMS microbiology reviews · 2025Review
- Exploring the bioactive landscape: peptides and non-peptides from the human microbiota.NPJ biofilms and microbiomes · 2025Review
- Examining the healthy human microbiome concept.Nature reviews. Microbiology · 2025Review
- Dynamic characterization of the changes in intestinal fungi and fecal metabolites during the reproductive cycle of sows.Veterinary research communications · 2025Article
- Implication of Gut Mycobiome and Virome in Type-2 Diabetes Mellitus: Uncovering the Hidden Players.Phenomics (Cham, Switzerland) · 2025Review
- The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications.Molecular cancer · 2025Review
- Succinate-producing microbiota drives tuft cell hyperplasia to protect against Clostridioides difficile.The Journal of experimental medicine · 2025Article
- Fungi in the Gut Microbiota: Interactions, Homeostasis, and Host Physiology.Microorganisms · 2025Review
- Metagenomics reveals unique gut mycobiome biomarkers in major depressive disorder - a non-invasive method.Frontiers in cellular and infection microbiology · 2025Article
- Gut mycobiota dysbiosis and systemic immune dysfunction in Chinese schizophrenia patients with metabolic syndrome.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Fungal communities (mycobiome) have an important role in sustaining the resilience of complex microbial communities and maintenance of homeostasis. The mycobiome remains relatively unexplored compared to the bacteriome despite increasing evidence highlighting their contribution to host-microbiome interactions in health and disease. Despite being a small proportion of the total species, fungi constitute a large proportion of the biomass within the human microbiome and thus serve as a potential target for metabolic reprogramming in pathogenesis and disease mechanism. Metabolites produced by fungi shape host niches, induce immune tolerance and changes in their levels prelude changes associated with metabolic diseases and cancer. Given the complexity of microbial interactions, studying the metabolic interplay of the mycobiome with both host and microbiome is a demanding but crucial task. However, genome-scale modelling and synthetic biology can provide an integrative platform that allows elucidation of the multifaceted interactions between mycobiome, microbiome and host. The inferences gained from understanding mycobiome interplay with other organisms can delineate the key role of the mycobiome in pathophysiology and reveal its role in human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.